Full Press Release Details
MEDIA ADVISORY - Oncolytics Biotech Inc. Announces Participation
in the Canaccord Genuity 36th Annual Growth Conference
CALGARY, Aug. 10, 2016 /CNW/ - Dr. Brad Thompson, President
and CEO of Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY), will present at the 36th Annual Canaccord Genuity
Growth Conference in a session on Thursday, August 11th, 2016 at 11:00 a.m. ET. The conference takes place
on August 10th and 11th in Boston, MA.
A live audio link to the webcast session will be available
A link to the presentation will also be available on the company's
website at: http://www.oncolyticsbiotech.com/investor-centre/presentations/. It is recommended that listeners log on 10 minutes
in advance of a live presentation to register and download any necessary software. Links to the audio replays will be accessible
following the presentations on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused
on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety
of later-stage, randomized human trials in various indications using REOLYSIN , its proprietary formulation of the
human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
The session and webcast times are subject to change. This
release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays,
uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements.
Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion
of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related
to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned
against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements,
except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
For further information: NATIONAL Equicom: Nick Hurst, 320
Front Street W, Suite 1600, Toronto, Ontario, M5V 3B6, Tel: 416.586.1942, nhurst@national.ca; NATIONAL Equicom: Michael Moore,
San Diego, CA, Tel: 858.886.7813, mmoore@national.ca; Dian Griesel, Inc.: Susan Forman, 335 West 38th Street, 3rd Floor, New York,
NY 10018, Tel: 212.825.3210, sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 17:00e 10-AUG-16